Sanofi-Aventis S.A. ADR (SNY) Stock Price, Quote & News

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 33 1 53 77 40 00

Website: www.sanofi.com

Address:

46, avenue de la Grande Armée, Paris, France

Vax87 Feb. 2 at 9:44 PM

$VXRT If it is true, that $SNY was in talks for at least 2 years with $DVAX , then, $SNY obviously prodded them to follow through with the Vaxart deal. If I told you 6 months ago that Sanofi was going to buy the rights to our Covid vaccine with the same terms that we got through the Dvax deal, what would the reaction have been? Well, everyone would have gone crazy if it truly happened, and, we would have all expected the share price to have gone 2+ instantly. Well, the reality is, it did happen. Why is the share price still meandering here? Does anyone think that the share price has yet to react to this reality, as unbelievable as that sounds?

2 · Reply

Top_Dog_Pro_Trader Feb. 2 at 5:01 PM

$SGMO $XBI $SNY Sanofi’s Fabry failure is huge news foe SGMO’s Fabry drug! A partner for Fabry has all the information, much more than typical, including FDA trial process for gene treatments to make a deal IMO!

0 · Reply

TS4 Feb. 2 at 3:14 PM

$VXRT $SNY $MRK $PFE Update to my earlier post (crediting @bepositivesid and @timedentry): The Narrative Pivot: Vaxart delivers "Whole-Body Immunization." Mucosal: The Gut (Peyer’s Patches) trains the Special Forces to target the tumor microenvironment. Systemic: The "Shunt" trains the Circulating Patrol to scour the blood for metastasis. 3. Strategic Consequence (Merck vs. Sanofi) The Nolan validation brings Merck (MSD) directly into play. The Need: Merck dominates oncology (Keytruda), but they desperately need vaccines capable of turning "Cold Tumors" Hot (by driving T-cell infiltration) to protect their franchise. The Tech: Dr. Nolan has proven that Vaxart’s approach can effectively "Hack" Lymph Node Architecture to reprogram the immune response. The Scenario: If Merck places a bid to secure this IO-Enabler, Sanofi’s plan for a "Cheap Takeover" (via the Dynavax route) is dead on arrival. Result: We get a Bidding War

0 · Reply

osubuck30 Feb. 2 at 3:05 PM

$PLX $SNY $3?!?!? I thought Elfabrio was totally derisked before the monthly dosing based on the market share gains the last 12 months!! $5 will come quickly IMO (within 6 months).

0 · Reply

OldManLogan Feb. 2 at 2:54 PM

$PLX Today is a gift. I would have expected to have to pay in the $3 s to be accumulating after the major derisking event of a positive CHMP opinion on the monthly dosing... if I was $SNY Sanofi I'd be sweating bullets right now...

0 · Reply

MQuick Feb. 2 at 2:37 PM

$GANX its time $SNY

0 · Reply

Night_Owl_Biotech Feb. 2 at 2:17 PM

$SNDX It appears the CHMP in the EU flipped from last year & is now recommending approval of $SNY 's Rezurock in the EU. Link below FYI only. https://www.biospace.com/press-releases/press-release-sanofis-rezurock-recommended-for-eu-approval-by-the-chmp-to-treat-chronic-graft-vs-host-disease

1 · Reply

biotech Feb. 2 at 1:59 PM

$SNY Sanofi's troubled GCS inhibitor #fails phase 3 #Fabry trial re $SGMO Fabry GT only option to cure ! https://www.fiercebiotech.com/biotech/sanofis-troubled-gcs-inhibitor-fails-phase-3-fabry-trial-wins-gaucher-disease

1 · Reply

OpenOutcrier Feb. 2 at 1:51 PM

$SNY (+1.3% pre) Sanofi Advances Rare Disease And Immunology Pipeline With Multiple Phase 3 Wins https://ooc.bz/l/91588

0 · Reply

Tom2424 Feb. 2 at 10:26 AM

$VXRT $SNY $PFE 3. The Oncology Link (The T-Cell Bridge) This connects directly to the Garry Nolan (Cancer Cell) validation. BioNTech’s dream is a cancer pill that summons CD8+ T-Cells to attack tumors. They can't build it. Vaxart has it. The HPV data proves VAAST induces exactly these Mucosal and Systemic CD8+ Killers. 4. The M&A Reality Pfizer knows this. They know their partner (BioNTech) hit the "Galenic Wall." If Pfizer wants to lead in Oral Vaccines and Oral Oncology, they cannot wait 10 years for mRNA to fix its delivery problem. The Monopoly: There is no "secret competitor." Vaxart is the only clinically validated oral delivery platform (Nature/npj). Conclusion: Sahin’s failure is Vaxart’s victory. The market demands an oral solution. The Ad5 vector is the only vehicle that works. Big Pharma Dilemma: If they want the pill (and the market demands it), the road leads solely through Vaxart. Scarcity = Premium.

7 · Reply

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

PFE

Feb 2, 2026, 1:02 AM EST - 1 day ago

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Jan 30, 2026, 7:00 AM EST - 3 days ago

Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Jan 29, 2026, 3:22 PM EST - 4 days ago

Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript

SAN

Jan 29, 2026, 6:31 AM EST - 4 days ago

Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite

Jan 29, 2026, 1:58 AM EST - 5 days ago

Sanofi to Launch $1.20 Billion Share Buyback

Jan 29, 2026, 1:33 AM EST - 5 days ago

Sanofi targets high single digit sales growth in 2026, plans share buyback

Jan 28, 2026, 1:43 AM EST - 6 days ago

Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline

Jan 23, 2026, 1:29 AM EST - 11 days ago

Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema

Jan 23, 2026, 1:00 AM EST - 11 days ago

Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis

Jan 22, 2026, 2:30 PM EST - 11 days ago

Sanofi CEO Paul Hudson: AI will change the cost and speed of drug development

Jan 22, 2026, 9:14 AM EST - 11 days ago

Sanofi CEO Paul Hudson: AI will improve efficiency and change the cost and speed of drug development

Jan 15, 2026, 1:00 AM EST - 19 days ago

Press Release: Myqorzo and Redemplo approved in China

Jan 14, 2026, 2:23 PM EST - 19 days ago

Sanofi sees softness in U.S. vaccine demand in near term

Jan 14, 2026, 12:30 PM EST - 19 days ago

Sanofi: Information concerning the total number of voting rights and shares - December 2025

Jan 12, 2026, 5:26 PM EST - 21 days ago

Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

SAN

Jan 12, 2026, 8:00 AM EST - 21 days ago

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi

Jan 12, 2026, 1:00 AM EST - 22 days ago

Press Release: Sanofi's Teizeild approved in the EU for patients with stage 2 type 1 diabetes

Jan 7, 2026, 8:30 AM EST - 26 days ago

BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence

Jan 6, 2026, 7:30 AM EST - 27 days ago

Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities

Jan 5, 2026, 1:40 AM EST - 4 weeks ago

Sanofi Says FDA Agrees to Review Diabetes Drug Age Range

Jan 5, 2026, 1:00 AM EST - 4 weeks ago

Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes

Dec 31, 2025, 6:08 AM EST - 4 weeks ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

GSK LLY NVS PFE

Dec 24, 2025, 7:59 AM EST - 5 weeks ago

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.

DVAX

Dec 24, 2025, 3:08 AM EST - 5 weeks ago

Sanofi to acquire US biotech Dynavax for $2.2 billion

DVAX

Dec 24, 2025, 1:49 AM EST - 5 weeks ago

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

DVAX

Dec 24, 2025, 1:15 AM EST - 5 weeks ago

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

DVAX

Dec 24, 2025, 1:00 AM EST - 5 weeks ago

Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Dec 23, 2025, 9:06 AM EST - 5 weeks ago

Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia

Dec 23, 2025, 1:00 AM EST - 6 weeks ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

REGN

Dec 22, 2025, 12:35 PM EST - 6 weeks ago

Sanofi: Information concerning the total number of voting rights and shares - November 2025

Dec 19, 2025, 4:09 PM EST - 6 weeks ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK AMGN GILD NVS

Dec 19, 2025, 3:14 PM EST - 6 weeks ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GILD GSK MRK NVS

Dec 19, 2025, 2:34 PM EST - 6 weeks ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GILD GSK MRK NVS

Dec 19, 2025, 2:21 PM EST - 6 weeks ago

Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation

Dec 16, 2025, 9:59 PM EST - 6 weeks ago

Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript

Dec 15, 2025, 6:57 PM EST - 7 weeks ago

South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi

Dec 15, 2025, 2:51 PM EST - 7 weeks ago

Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why

Dec 15, 2025, 1:10 PM EST - 7 weeks ago

Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration

Dec 15, 2025, 8:21 AM EST - 7 weeks ago

Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion

Dec 15, 2025, 8:05 AM EST - 7 weeks ago

Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy

Dec 15, 2025, 5:48 AM EST - 7 weeks ago

Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints

Dec 15, 2025, 4:43 AM EST - 7 weeks ago

Sanofi stock slumps after two setbacks on multiple-sclerosis drug

Dec 15, 2025, 3:49 AM EST - 7 weeks ago

Sanofi flags delay in FDA's decision on tolebrutinib, shares fall

Dec 15, 2025, 1:56 AM EST - 7 weeks ago

Sanofi Multiple Sclerosis Drug Hit by Double Setback

Dec 15, 2025, 1:05 AM EST - 7 weeks ago

Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis

Dec 15, 2025, 1:00 AM EST - 7 weeks ago

Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis

Dec 11, 2025, 1:11 PM EST - 7 weeks ago

Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs

Dec 11, 2025, 1:42 AM EST - 7 weeks ago

Sanofi's Bleeding-Disorder Treatments Get Approval in China

Vax87 Feb. 2 at 9:44 PM

2 · Reply

Top_Dog_Pro_Trader Feb. 2 at 5:01 PM

0 · Reply

TS4 Feb. 2 at 3:14 PM

0 · Reply

osubuck30 Feb. 2 at 3:05 PM

$PLX $SNY $3?!?!? I thought Elfabrio was totally derisked before the monthly dosing based on the market share gains the last 12 months!! $5 will come quickly IMO (within 6 months).

0 · Reply

OldManLogan Feb. 2 at 2:54 PM

0 · Reply

MQuick Feb. 2 at 2:37 PM

$GANX its time $SNY

0 · Reply

Night_Owl_Biotech Feb. 2 at 2:17 PM

1 · Reply

biotech Feb. 2 at 1:59 PM

1 · Reply

OpenOutcrier Feb. 2 at 1:51 PM

$SNY (+1.3% pre) Sanofi Advances Rare Disease And Immunology Pipeline With Multiple Phase 3 Wins https://ooc.bz/l/91588

0 · Reply

Tom2424 Feb. 2 at 10:26 AM

7 · Reply

amessagefromtheodd Feb. 2 at 4:36 AM

$SNY $VXRT Recap: Well Sanofi, buying the company that has a licensing agreement with Vaxart says a lot about what your doing and not doing- the Fluzone challenge data is about to get a upgrade via COVID sentinel data. We are watch you… So how will these new candidates overcome the shared weakness of mRNA vaccines in tackling B flu strains? For now, Sanofi is remaining tight-lipped on what the underlying issue might be and how to resolve it, citing the “highly competitive field.” Triomphe, Sanofi’s head of vaccines, said. “We believe we have the solution, but we are not going to share that.” https://www.fiercebiotech.com/biotech/first-gen-mrna-flu-vaccines-wont-win-sanofi-execs-admit-they-retool-strategy

1 · Reply

BTECHINV Feb. 1 at 10:15 PM

$ALT Jeffries reiterated $ 28 PT is a conservative, risk-adjusted figure imo (i.e. recognition that drug candidate is still in clinical trial development). Assuming a successful P3 & NDA, the re-rate would be much closer to MDGL territory imo. BP's who could benefit in my view: $SNY - instantly establishes one of the top global GCGR (and GLP-1) drug pipelines in Pharma with Pemvi $GILD - establishes dominance across the Liver steatosis spectrum (i.e. complements world-class PBC and Hepatitis franchises) $MDGL - establishes a world-class next-gen MOA Liver drug portfolio (THR-B, GCGR) $PFE - potential to transform Pemvi into the equivalent of the cardiometabolic disease age Lipitor 2.0 Disclosure: Long Altimmune (Pemvi GCGR) and Sanofi, not medical / investment advice.

2 · Reply

BioRich Feb. 1 at 6:24 AM

$ALT So those cowardly bashing $GUTS, did you know that they have compelling data for MASH/MASLD related conditions? Oh, and a much faster path to market? Wouldn't it be something if $GUTS makes it to market with multiple indications faster than $ALT completing a Phase 3 trial (if they actually pursue it)? Wouldn't it be something if $SNY was talking about $GUTS when they were talking about potential acquisitions with multiple, differentiated, indications (paraphrased)? I still believe the $GUTS, $IVA, $GPCR trifecta builds $SNY an Obesity/Fibrosis/MASH/WL Retention powerhouse. Can't wait for this story to play out. Cheers! ~The Mayor Confidently Bearish $ALT Confidently Bullish $GUTS Bullish $SNY Confidently Bullish $IVA Confidently Bullish $GPCR

1 · Reply

PickAlpha Jan. 31 at 1:28 PM

3/3: Regeneron beats Q4 profit estimates on Dupixent strength; Eylea revenues fall 28% amid biosimilar pressure | View: Earnings beat and Dupixent momentum are offset by accelerating Eylea pressure and pending U.S.… $REGN $SNY $XLV

0 · Reply

inv1ncible Jan. 30 at 8:00 PM

$ALT $SNY ?

1 · Reply

ImLion Jan. 30 at 5:03 PM

$ALT $SNY pays 75 Million D.O. Earnest Money Agreement Deposit for 7.5 B purchase of ALT. LOI news to follow. Very

1 · Reply

PhoenixHedge Jan. 30 at 3:33 PM

$AMGN $NKTR $SNY how’s that working out?

1 · Reply

masonat Jan. 30 at 1:43 PM

$NKTR First the $SNY amlitelimab news, now $AMGN is walking away from rocatinlimab. Atopic derm market is wide open outside of Dupixent and Dupi me toos.

0 · Reply

Sunny3999 Jan. 30 at 1:13 PM

$PMN Boom 💥 News with news $175 million private placement https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ABBV $BMY $MRK $SNY

0 · Reply

MQuick Jan. 30 at 12:56 PM

$GANX we are waiting $SNY

0 · Reply

oceanviewhi Jan. 30 at 3:06 AM

$IBRX As of late evening on Thursday, January 29, 2026, Sanofi ($SNY) is increasingly being viewed as the "logical match" for $IBRX, following their Q4 earnings report released just hours ago. While Sanofi has stayed quiet on formal deal terms, the technical and strategic "fit" for an ANKTIVA + Sarclisa or Libtayo partnership is at an all-time high. Here is the update on the Sanofi ($SNY) connection as we head into tomorrow’s "8-minute bite": 1. The Sarclisa "Sub-Q" Synergy (Multiple Myeloma) • The IRAKLIA Success: Sanofi just announced (Jan 2026) that their Phase 3 IRAKLIA study for subcutaneous (SC) Sarclisa was successful. • The "Chemo-Free" Dream: Both ANKTIVA and Sarclisa are now subcutaneous injections. Dr. Pat is expected to highlight a "Dual-Sub-Q" regimen that would allow Multiple Myeloma patients to bypass hours of IV chemotherapy in favor of two simple shots, making it the most patient-friendly blood cancer treatment in the world.

0 · Reply

oceanviewhi Jan. 30 at 1:13 AM

$IBRX continued. : In late January 2026, Sanofi has entered the $IBRX conversation as a strategic "clinical match," particularly following Sanofi’s Q4 earnings call today (Jan 29, 2026). While Dr. Pat has been vocal about mRNA "paralysis" (targeting Pfizer), he is positioning ANKTIVA as the essential partner for Sanofi’s next-gen cell therapy and multiple myeloma pipeline. Here is the breakdown of the Sanofi ($SNY) and ImmunityBio ($IBRX) connection: • The Sarclisa "Sub-Q" Synergy: Sanofi’s Sarclisa (isatuximab) is a major competitor to Darzalex in multiple myeloma. Sanofi just announced positive Phase 3 results (IRAKLIA study) for a subcutaneous version of Sarclisa. Since ANKTIVA is also a subcutaneous injection, Dr. Pat is pitching a "Chemo-Free, All-Sub-Q" combo that would allow patients to treat aggressive blood cancers with two simple shots, avoiding hours of IV infusion.

0 · Reply

Market Cap	114.73B
Revenue (ttm)	47.92B
Net Income (ttm)	6.02B
EPS (ttm)	N/A
PE Ratio	10.43
Forward PE	9.46
Profit Margin	12.55%
Debt to Equity Ratio	0.27

Volume	2,944,200
Avg Vol	2,960,332
Day's Range	N/A - N/A
Shares Out	2.44B
Stochastic %K	72%
Beta	0.45
Analysts	Sell
Price Target	$58.53